Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer
Metrics: PDF 932 views | Full Text 1934 views | ?
Neelima Vidula1, Leif W. Ellisen1 and Aditya Bardia1
1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
|Neelima Vidula,||email:||[email protected]|
Keywords: cell-free DNA;
Received: November 19, 2020 Accepted: December 22, 2020 Published: January 19, 2021
Plasma based genotyping via cell-free DNA may identify actionable mutations for potential therapeutic intervention in patients with advanced malignancies including breast cancer. In this article, we discuss recent studies using cell-free DNA testing to identify and classify somatic BRCA1/2 mutations in metastatic breast cancer, and potential future applications for the treatment of metastatic breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.